Neuronetics : STIM Corporate Presentation March 2024

COMPANY PRESENTATION

NASDAQ: STIM

March 2024

Disclaimers

n e u r o s t a r . c o m

This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data.

Certain statements in this presentation and accompanying commentary that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as "outlook," "potential," "believe," "expect," "plan," "anticipate," "predict," "may," "will," "could," "would" and "should" as well as the negative of these terms and similar expressions. These statements include those relating to the Company's business outlook and current expectations for upcoming quarters and fiscal year 2024, including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this presentation. These risks and uncertainties include, without limitation, risks and uncertainties related to: the impact of public health crises on the Company's operations, manufacturing and supply chain interruptions or delays; the Company's ability to execute its business strategy; the Company's ability to achieve or sustain profitable operations due to its history of losses; the Company's reliance on the sale and use of its NeuroStar Advanced Therapy system to generate revenues; the scale and efficacy of the Company's salesforce; the Company's ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using the Company's products; physician and patient demand for treatments using the Company's products; developments in competing technologies and therapies for the indications that the Company's products treat; product defects; the Company's ability to obtain and maintain intellectual property protection for its technology; developments in clinical trials or regulatory review of NeuroStar Advanced Therapy system for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; our ability to successfully roll-out our Better Me Guarantee Provider Program on the planned timeline; our self-sustainability and existing cash balances; and our ability to achieve cash flow break-even in the fourth quarter of 2024 and on a full-year basis in 2025. For a discussion of these and other related risks, please refer to the Company's recent filings with the U.S. Securities and Exchange Commission (the "SEC"), which are available on the SEC's website at www.sec.gov. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this presentation. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information, future events, or changes in the Company's expectations.

2

Presenters	n e u r o s t a r . c o m
38+ years of experience	37+ years of experience

Keith Sullivan

President &

Chief Executive Officer

Steve Furlong

Executive Vice President,

Chief Financial Officer & Treasurer

3

Our Mission:

Renewing Lives by Transforming Neurohealth

NeuroStar Advanced Therapy for Mental Health

Prevalence

Adults with Major Depressive Disorder (MDD) (21 million US adults) or Obsessive-Compulsive Disorder (OCD) (4 million US adults)

Market Leader

Market leader in TMS for depression with over 6.1 million treatment sessions and over 169,000 patients treated

Sales & Customer Support

Largest direct sales and customer support team in the industry1

Reimbursement

Broad US reimbursement among commercial and government payors

Clinical Dataset

Largest clinical dataset in

TMS for depression

Outcomes Registry

Largest depression

outcomes registry in the world2

Indications & Growth

New indication opportunities and geographic expansion for growth (Anxious Depression and OCD added 2022)

4	1. Neuronetics, Inc. internal data on file 2024 | 2. Hutton TM, et al (2023) Brain Stim. 16(5):1510-1521.

Patients with Major Depressive Disorder are Underserved

21.0 MILLION

US Adults suffering

from MDD1

13.9 MILLION	US Patients
with MDD
being treated1
Current Solution:	6.4	Poorly served1,2,3
Antidepressant
Medications	MILLION

• Lack of Efficacy
• Intolerable Side Effects
• Increased Need for Solutions Post-COVID

5	1. https://www.nimh.nih.gov/health/statistics/major-depression.shtml, accessed 3/7/2022 | 2. Per STAR*D patients that have failed one or more antidepressant trial of adequate dose and duration

3. Journal of Clinical Psychiatry,accessed 3/7/2022

Our Unique Differentiators: Only NeuroStar Has…

Practice

Development

Manager

Delivers the

a proven framework to grow your NeuroStar practice

83% Response / 62% Remission1

z

Clinical results validated with

15 years of data via

the largest Outcomes Registry

Marketing Spend

To drive Consumer

Awareness

and grow the category. Increased

brand awareness by 33% in 2022.

6	1.	Sackeim HA, et al. (2020) J. Affect. Disord. 277:65-74. Based on a real-world, retrospective study using CGI-S and a sample size of 615 patients.

Limitations of Antidepressant Medications

The largest prospective clinical trial of MDD ever conducted, STAR*D, showed that treatment resistance causes a patient's chance for remission to decrease with each subsequent medication attempt.

STAR*D also showed discontinuation due to side effects increases with each medication attempt.

STAR*D Study n = 4,041

7	1. Trivedi (2006), Am J Psychiatry | 2. Rush (2006), Am J Psychiatry | 3. Fava (2006), Am J Psychiatry | 4. McGrath (2006), Am J Psychiatry

NeuroStar Delivers Proven Results

Real World Clinical Rating for Patients with MDD1

Significant relief in depression symptoms

Depression went away

8

1. Sackeim HA, et al. (2020) J. Affect. Disord. 277:65-74. Based on a real-world, retrospective study using CGI-S and a sample size of 615 patients.

Only NeuroStar Has…

Clinically Proven Durability Established Through 12 Months

Long-term post-acute treatment1

67.7%

45.1%

9	1. Dunner DL, et al. (2014). J Clin Psychiatry. 75(12):1394-1401

Only NeuroStar has…

Substantial Body of Clinical Evidence1

15>1,000

Studies Patients

Safety Record

• 6.1 million+ treatment sessions delivered globally
• Over 169,000 patients treated

Resulting in 31 Publications

Investigator-initiated Trials

• More than 65 studies with over 1,900 patients
• Wide range of conditions, including

• Low discontinuation rate from adverse events ~5%2

anxiety, bipolar disorder, pain, PTSD, addiction, schizophrenia, tinnitus, and others

10	1. Neuronetics, Inc. internal data on file 2024. | 2. O'Reardon et al. (2007) Biol Psychiat, 62(11):1208-1216.